Carol Robinson
Family · Warwick, RINPI 1316933757
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $71,715 of the $82,164 with a category attached, or 87.3%. AbbVie accounts for 61.2% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2021 at $30,443 and has fallen 87.4% since, to $3,826 in 2025. Among family clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 426 payments — averaging $192.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$50K
- Biohaven Pharmaceuticals, Inc.$13K
- Teva Pharmaceuticals USA, Inc.$7K
- Biohaven Pharmaceutical Holding Company Ltd.$6K
- Amgen$3K
- Pfizer$1K
- plus $2K from 10 others
What the payments were for
- Speaking & faculty fees$71,71587%
- Travel & lodging$3780%
- Food & beverage$10,07112%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 135 | $50,274 |
| Biohaven Pharmaceuticals, Inc. | 72 | $12,515 |
| Teva Pharmaceuticals USA, Inc. | 42 | $7,274 |
| Biohaven Pharmaceutical Holding Company Ltd. | 25 | $5,809 |
| Amgen | 18 | $3,226 |
| Pfizer | 46 | $1,076 |
| Lundbeck LLC | 44 | $1,067 |
| Lilly USA, LLC | 21 | $481 |
| Amneal Pharmaceuticals LLC | 9 | $164 |
| Axsome Therapeutics, Inc. | 3 | $80 |
| Impel Pharmaceuticals Inc. | 3 | $55 |
| Upsher-smith Laboratories LLC | 2 | $45 |
| Adamas Pharmaceuticals, Inc. | 2 | $35 |
| Novartis | 2 | $25 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| Life Molecular Imaging Ltd | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$82,164 in reported general payments places this provider in the 95th percentile of 457 family providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 77 | $109,695 |
| Aimovig AutoinjectorErenumab-Aooe | 123 | $106,631 |
| QuliptaAtogepant | 45 | $51,465 |
| Nurtec OdtRimegepant Sulfate | 39 | $38,919 |
| Emgality PenGalcanezumab-Gnlm | 49 | $32,474 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 15 | $22,285 |
| BotoxOnabotulinumtoxina | 11 | $14,598 |
| Tegretol XrCarbamazepine | 11 | $9,830 |
| Sumatriptan Succinate | 259 | $8,290 |
| Zolmitriptan | 15 | $5,397 |
| Gabapentin | 169 | $4,992 |
| Frovatriptan Succinate | 19 | $3,476 |
| Memantine Hcl | 48 | $3,384 |
| Amitriptyline Hcl | 119 | $2,960 |
| Carbamazepine | 33 | $2,438 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta, Botox | $50,274 | $175,758133 claims |
| PfizerNurtec Odt | $1,076 | $38,91939 claims |
| Upsher-smith Laboratories LLCTopiramate | $45 | $1,583130 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 457 family providers in Rhode Island.
Other family in Warwick
- Alicia VatterWarwick$15K
- Talia LeuropaWarwick$7K
- Shelby DefariaWarwick$4K
- Kayla BabcockWarwick$4K
- Ellen HofferWarwick$3K
- Mark ClarkeSmithfield$37K
- Olga FedorenkoCoventry$24K
- Kaleigh RapozaJohnston$14K
- David RamosRiverside$14K
- Sharon BensonNorth Smithfield$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.